Investigational drug · Phase 2
ERX1000
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Obesity & Overweight.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ERX1000"
First trial start
2026
May 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ERX1000", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity & Overweight
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "ERX1000" as an intervention, largest first.
ERX PharmaceuticalsIndustry
NCT07570758 · 80 participants (planned) · Start May 28, 2026 · Primary completion May 2027
Drug: ERX1000 · For: Obesity & Overweight
Sites: Louisville, Kentucky; Monroe, North Carolina; North Charleston, South Carolina
ERX PharmaceuticalsIndustry
NCT04890873 · 48 participants · Start Oct 17, 2019 · Primary completion Jul 3, 2023
Drug: ERX1000; Placebo · For: Obesity
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity & Overweight
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- LUM-201Phase 36 trials
Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight
- HDM1005 1Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Obesity & Overweight
- HDM1005 2Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Obesity & Overweight
- SemagludtidePhase 32 trials
Lumos Pharma · Obesity & Overweight, Early Alzheimer's Disease
- EnobosarmPhase 22 trials
Veru Inc. · Obesity & Overweight, Mobility Disability, HOMA-IR
- BIO101Phase 21 trial
Biophytis · Muscle Wasting, Obesity & Overweight, Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.